Institutional News
- A Phase II Study of Amivantamab SC (Subcutaneous) in Participants With MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY) This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug directed against the MET gene. The primary objective is to evaluate the objective response rate (ORR).
Click her to see the study protocol
For more information or to refer a patient, please contact UC Davis Comprehensive Cancer Center, Office of Clinical Research via email at OCRReferral@health.ucdavis.edu or by phone at 916-382-6970.
Updates from ASCO
The American Society of Clinical Oncology and Conexiant have launched ASCO AI in Oncology, a new digital platform dedicated to helping oncology professionals navigate the rapidly evolving world of artificial intelligence. This trusted resource provides curated, expert-led insights, practical education on enhancing diagnostic accuracy and workflows, and a space for global clinicians to share real-world implementation experiences. READ MORE
“Massive Shift” Prompts ASCO to Update Guideline for Multiple Myeloma.
READ MORE
New data published in the American Cancer Society’s (ACS) Cancer Statistics, 2026 report show that, for the first time, the 5-year survival rate for all cancers combined has reached 70% for individuals diagnosed during 2015 to 2021 in the United States. In addition, those diagnosed with high-mortality cancers and advanced diagnoses experienced the largest gains in survival.
READ MORE
Corporate Member News
FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).
READ MORE
FDA approved pembrolizumab (Keytruda, Merck) as well as pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.
READ MORE
New Publication Alert: Learn More About Real-World Outcomes in ER+/HER2- ESR1-Mutant Metastatic Breast Cancer
Clinical Cancer Research has recently featured two complimentary publications detailing the outcomes of patients administered an oral SERD with ESR1-mutant metastatic breast cancer
Lloyd et al., 2025
Rugo et al., 2025
